Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2024
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined with the Dow down 0.97%, Nasdaq falling over 150 points, and S&P 500 dropping 0.77%. Energy shares rose by 0.6%, while utilities fell by 1.7%.
International Market Updates: European shares mostly increased, with retail sales in the Eurozone rising 0.2% in August. Asian markets were mixed, with Japan's Nikkei gaining 1.80% and India's BSE Sensex dipping 0.78%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.00 USD with a low forecast of 42.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.340
Low
42.00
Averages
50.00
High
60.00
Current: 44.340
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Executive Sells Shares, Investor Implications
- Executive Stock Sale: On January 22, 2026, Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares for approximately $695,937, indicating executive activity in the market and raising investor interest in the company's future performance.
- Ownership Proportion Change: Following this transaction, Qatanani's direct ownership decreased to 85,660 shares, representing only 21% of total holdings, which may affect investor confidence in his commitment to the company's future.
- Trading Plan Context: The stock sale was executed under a Rule 10b5-1 trading plan, indicating that the transaction was pre-scheduled rather than a spontaneous decision, which mitigates potential negative interpretations of insider selling.
- Future Product Outlook: Scholar Rock plans to launch its key product candidate, apitegromab, in 2026, and if approved by the FDA and other global agencies, it could significantly enhance the company's market position in treating spinal muscular atrophy, thereby increasing its investment appeal.
Continue Reading
Scholar Rock Executive Sells Shares
- Share Sale Transaction: Mo Qatanani, Chief Scientific Officer of Scholar Rock, sold 14,898 shares on January 22, 2026, for approximately $695,938 at a weighted average price of $46.71 per share, representing a 14.82% reduction in his direct holdings, leaving him with 85,660 shares, or 0.08% of the outstanding shares.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan, indicating that it was not a voluntary action by Qatanani but rather a pre-scheduled transaction designed to ensure compliance and mitigate insider trading risks.
- Future Product Plans: Scholar Rock aims to launch its key product candidate, apitegromab, in the U.S. and European markets in 2026, which is touted as the world's first muscle-targeted treatment for spinal muscular atrophy (SMA); success in this endeavor could significantly enhance the company's market outlook.
- Financial Status and Market Performance: Despite only a 2% stock increase in 2025 and ongoing net losses, the potential success of the apitegromab project could make SRRK a more attractive investment option, likely drawing increased investor interest.
Continue Reading